Cell Reports, Volume 40

Supplemental information

The generation of stem cell-like memory cells

early after BNT162b2 vaccination is associated

with durability of memory CD8⁺ T cell responses

Sungmin Jung, Jae Hyung Jung, Ji Yun Noh, Woo-Joong Kim, Soo-Young Yoon, Jongtak Jung, Eu Suk Kim, Hong Bin Kim, Hee Jin Cheong, Woo Joo Kim, Su-Hyung Park, Kyoung-Ho Song, Joon Young Song, and Eui-Cheol Shin

Table S1. Characteristics of the BNT162b2-vaccinated individuals with SARS-CoV-2 MHC class I multimer⁺CD8⁺ T cells, Related to Figures 1-4.

Donor number	Do	nor charact	eristics		Time points (days post-vaccination)											
				Multimer	Pre-vaccination	Post	-first	Post-second								
	Sex	Age (yr)	HLA type		0	1 week	3 weeks	1-2 weeks	1-2 weeks 3 weeks		24 weeks					
7	М	44	HLA-A*02	S269, S1000	0	7 18		7	21	84	168					
15	F	30	HLA-A*02	S ₂₆₉	0	9	20	8	22	87	170					
16	F	28	HLA-A*02	S269, S1000	0	8	19	8	21	86	169					
21	М	34	HLA-A*02	S ₂₆₉	0	8	19	8	21	86	173					
22	М	34	HLA-A*02	S ₂₆₉	0	7	20	7	25	85	168					
24	F	24	HLA-A*02	S ₂₆₉	0	9	20	8	22	84	170					
28	F	38	HLA-A*02	S ₂₆₉	0	8	19	8	21	84	168					
30	F	56	HLA-A*02	S ₂₆₉	0	9	20	8	22	84	170					
32	F	29	HLA-A*02	S ₂₆₉	0	8	19	8	21	84	166					
33	F	35	HLA-A*02	S269, S1000	0	8	19	8	21	86	169					
45	F	28	HLA-A*02	S ₂₆₉	0	7	18	11	21	86	169					
78	F	27	HLA-A*02	S ₂₆₉	0	7	21	8	21	84	169					

Yr, year; M, male; F, female.

Table S2. Characteristics of the BNT162b2-vaccinated individuals with SARS-CoV-2 MHC class I multimer⁺CD8⁺ T cells, Related to Figure 4.

Donor number	Dor	nor characte	eristics		Time points (days post-vaccination)											
				Multimer	Pre-vaccination	Post	-first	Post-second								
	Sex	Age (yr)	HLA type		0	1 week	3 weeks	1-2 weeks	3 weeks	12 weeks	24 weeks					
20	F	42	HLA-A*24	S448	0	NA	NA	7	NA	NA	164					
25	F	25	HLA-A*24	S448	0	NA	NA	8	NA	NA	170					
BH67	F	26	HLA-A*02	S ₂₆₉	0	NA	NA	15	NA	NA	154					
BH68	F	26	HLA-A*02	S ₂₆₉	0	NA	NA	13	NA	NA	154					
BH70	F	31	HLA-A*02	S ₂₆₉	0	NA	NA	13	NA	NA	153					
BH71	F	33	HLA-A*02	S ₂₆₉	0	NA	NA	14	NA	NA	155					
BH72	F	30	HLA-A*02	S ₂₆₉	0	NA	NA	13	NA	NA	153					
BH73	F	27	HLA-A*02	S ₂₆₉	0	NA	NA	14	NA	NA	159					
BH78	F	28	HLA-A*02	S ₂₆₉	0	NA	NA	13	NA	NA	152					
BH82	F	26	HLA-A*02	S ₂₆₉	0	NA	NA	14	NA	NA	157					

Yr, year; M, male; F, female.

Data		Frequency of multimer*CD8* T cells (Fig. 1)								CD38/HLA-DR/CD127/KLRG1 expression on multimer*CD8* T cells (Fig. 2)						T-bet/Bcl-2/Ki-67 expression on multimer⁺CD8⁺ T cells (Fig. 2)					Differentiation of multimer*CD8* T cells (Fig. 3)						Correlation (Fig. 4)	
	Multimer	Time points (weeks post-vaccination)																										
Donor number		Pre-vaccination	Post-first		Post-second			Post-first		Post-second				Post	-first	Post-second			Post	-first	Post-second				Post-second			
number		0	1	3	1	3	12	24	1	3	1	3	12	24	1	3	1	3	12	24	1	3	1	3	12	24	1-2	24
N07	S ₂₆₉	0	0	0	0	0	0	0		0	0	0				0	0	0	0	0	0	0	0	0	0		0	0
N15	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
N16	S ₂₆₉	0	0	0	0	0	0	0		0			0	0		0			0		0	0	0	0	0	0	0	0
N21	S ₂₆₉	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0			0		0	0	0	0	0	0
N22	S ₂₆₉			0	0	0	0	0		0		0		0		0		0				0	0	0	0	0	0	0
N24	S ₂₆₉			0	0	0	0	0		0	0		0	0		0	0		0			0	0	0	0	0	0	0
N28	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
N30	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0		0	0	0	0	0	0	0	0
N32	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0			0	0	0	0	0		0	0	0	0	0		0	0
N33	S ₂₆₉		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
N45	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
N78	S ₂₆₉	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table S3. Profiling details of the BNT162b2-vaccinated individuals with SARS-CoV-2 MHC class I multimer⁺CD8⁺ T cells, Related to Figures 1-4.



Figure S1. Detection of SARS-CoV-2 S-specific multimer⁺**CD8**⁺ **T cells and validation, Related to Figure 1.** (A) Characteristics of SARS-CoV-2 S-specific MHC-I multimers utilized in this study.

(B) Gating strategy used for the detection of SARS-CoV-2 S-specific multimer⁺CD8⁺ T cells.

(C) S_{996} and S_{1220} -specific T-cell lines were generated by stimulating PBMCs from HLA-A*02(+) donors who recovered from SARS-CoV-2 infection with S_{996} (LITGRLQSL) or S_{1220} (FIAGLIAIV) peptides and recombinant human IL-2 (200 U/mL) for 2 weeks. Examples of S_{996} or S_{1220} multimer staining are presented. (D) S_{269} -specific and S_{448} -specific T-cell lines were generated by stimulating PBMCs from HLA-A*02(+)24(-) and HLA-A*02(-)24(+) BNT162b2-vaccinated individuals with S_{269} (YLQPRTFLL) and S_{448} (NYNYLYRLF) peptides and recombinant human IL-2 (200 U/mL), respectively, for 2 weeks. The generated T cells were successfully stained with the corresponding multimer: HLA-A*021 S_{269} or HLA-A*2402 S_{448} . However, multimer⁺ cells were not detected in HLA-mismatched cross-staining.

(E-F) Representative flow cytometry plots showing S_{269} multimer⁺ cells after S_{269} peptide stimulation of CTV-labeled PBMCs for (E) 120 h or (F) 6 h.

(G) Validation of MHC-I multimer-combined IFN- γ intracellular staining (ICS). IFN- γ ICS was performed with or without S₂₆₉ multimer staining using PBMCs from BNT162b2-vaccinated individuals (n=4; PBMCs obtained 6 months post-second vaccination). Left: Representative flow cytometry plots showing PBMCs from one individual. Right: Summary graph showing the frequency of IFN- γ^+ cells among CD8⁺ T cells. Statistical analysis was performed using paired Wilcoxon signed rank test (n.s., not significant).



Figure S2. UMAP plot of S_{269} multimer^+CD8^+ T cells in BNT162b2-vaccinated individuals over time, Related to Figure 2.

Pooled S_{269} multimer⁺CD8⁺ T cells from multiple patients. (A) Multimer⁺ cells expressing the indicated markers. (B) Multimer⁺ cells exhibiting each memory subset. Each time point consists of 4-5 patients with a total of 650-750 cells.



Figure S3. Phenotypes of $\rm S_{269}$ multimer^+CD8^+ T cells in BNT162b2-vaccinated individuals over time, Related to Figure 2.

(A-C, E) Representative flow cytometry plots showing the percentages of indicated subpopulations among S_{269} multimer⁺CD8⁺ T cells.

(D, F) Flow cytometry plots showing the staining of fluorescence-minus-one (FMO) controls for Ki-67, Bcl-2, KLRG1, and CD127.

(G) Normalized MFI of CD127 (MFI of CD127 on S_{269} multimer⁺CD8⁺ T cells / MFI of CD127 on CD8⁺CD127⁻ T cells) in vaccinated individuals over time summarized in box graphs. Post-first 1 week (n=8) and 3 weeks (n=12); post-second 1-2 weeks (n=10), 3 weeks (n=10), 12 weeks (n=9) and 24 weeks (n=9). Statistical analysis was performed using unpaired Mann-Whitney U test (***p < 0.001, ****p < 0.0001, n.s., not significant). MFI, median fluorescence intensity.



Figure S4. Differentiation kinetics of S₂₆₉ multimer⁺CD8⁺ T cells in BNT162b2-vaccinated individuals over time, Related to Figure 3.

(A) Flow cytometry plots showing the expression of CCR7 and CD45RA on total CD8⁺ T cells. (B) Representative flow cytometry plots showing the expression of T cell differentiation markers CCR7, CD45RA, and CD95 among S₂₆₉ multimer⁺CD8⁺ T cells. (C) Frequency of T_{SCM} cells among S₂₆₉ multimer⁺ cells compared between convalescent and vaccinated individuals 3-4 weeks (n=5 vs. n=12), 11-13 weeks (n=5 vs. n=12), and after 24 weeks (n=3 vs. n=10) post-symptom onset or post-second vaccination. The data of convalescent individuals were retrieved from our previous study (Jung et al., 2021). Statistical analysis was performed using unpaired Mann-Whitney U test (**p < 0.01, n.s., not significant).



Figure S5. Correlation between the frequency of SARS-CoV-2 S-specific MHC-I multimer⁺CD8⁺ T cells, T_{SCM} cells and age, Related to Figure 4.

(A-B) Correlation graphs showing the relationship between the frequency of T_{SCM} cells among CD3⁺ T cells or live cells 1-2 weeks post-second vaccination and (A) the frequency of SARS-CoV-2 S-specific multimer⁺CD8⁺ T cells 6 months post-second vaccination or (B) 6-month durability of S-specific multimer⁺CD8⁺ T cells (red = S_{269} , n=20; green = S_{448} , n=2) with black lines representing linear regression.

(C-D) Correlation between the frequency of multimer⁺ cells among CD8⁺ T cells 6 months postsecond vaccination and (C) donor age or (D) the percentage of T_{SCM} cells among multimer⁺ cells 1-2 weeks post-second vaccination (red = S_{269} , n=20; green = S_{448} , n=2) with black lines representing linear regression.

Statistical analysis was performed using Spearman correlation test with linear regression analysis (***p < 0.001).